# Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/antitumor-activity-of-nivolumab-on-hemodialysis-after-renal-allograft-rejection/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael Ong,Andrea Marie Ibrahim,Samuel Bourassa‐Blanchette,Christina Canil,Todd Fairhead,Greg Knoll |
| Citations | 81 |
| DOI | 10.1186/s40425-016-0171-8 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-016-0171-8 |
| OpenAlex ID | https://openalex.org/W2529221862 |
| PMID | 27777773 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Todd Fairhead](https://scholariq.org/researchers/todd-fairhead/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.